215 related articles for article (PubMed ID: 17240107)
21. Antimicrobial susceptibility of anaerobic bacteria in Bulgaria.
Marina M; Ivanova M; Kantardjiev T
Anaerobe; 2009 Aug; 15(4):127-32. PubMed ID: 19292999
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
[TBL] [Abstract][Full Text] [Related]
23. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
[TBL] [Abstract][Full Text] [Related]
25. Tinidazole inhibitory and cidal activity against anaerobic periodontal pathogens.
Alou L; Giménez MJ; Manso F; Sevillano D; Torrico M; González N; Granizo JJ; Bascones A; Prieto J; Maestre JR; Aguilar L
Int J Antimicrob Agents; 2009 May; 33(5):449-52. PubMed ID: 19097755
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
Cereda RF; Azevedo HD; Girardello R; Xavier DE; Gales AC;
Braz J Infect Dis; 2011; 15(4):339-48. PubMed ID: 21861004
[TBL] [Abstract][Full Text] [Related]
27. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Liu CY; Huang YT; Liao CH; Yen LC; Lin HY; Hsueh PR
Antimicrob Agents Chemother; 2008 Sep; 52(9):3161-8. PubMed ID: 18625771
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
Nord CE; Olsson-Liljequist B
Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
[TBL] [Abstract][Full Text] [Related]
29. [Identification of anaerobic bacteria isolated from various clinical specimens and determination of antibiotic susceptibilities].
Doğan M; Baysal B
Mikrobiyol Bul; 2010 Apr; 44(2):211-9. PubMed ID: 20549955
[TBL] [Abstract][Full Text] [Related]
30. Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole.
Dubreuil LJ; Mahieux S; Neut C; Miossec C; Pace J
Int J Antimicrob Agents; 2012 Jun; 39(6):500-4. PubMed ID: 22521766
[TBL] [Abstract][Full Text] [Related]
31. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections.
Odou MF; Muller C; Calvet L; Dubreuil L
J Antimicrob Chemother; 2007 Apr; 59(4):646-51. PubMed ID: 17350985
[TBL] [Abstract][Full Text] [Related]
33. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007.
Jamal W; Shahin M; Rotimi VO
Anaerobe; 2010 Feb; 16(1):1-5. PubMed ID: 19406247
[TBL] [Abstract][Full Text] [Related]
34. [Use of the Etest method for antimicrobial susceptibility testing of obligate anaerobes].
Rokosz A; Sawicka-Grzelak A; Kot K; Meszaros J; Łuczak M
Med Dosw Mikrobiol; 2001; 53(2):167-75. PubMed ID: 11757426
[TBL] [Abstract][Full Text] [Related]
35. In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds.
Hoellman DB; Kelly LM; Jacobs MR; Appelbaum PC
Clin Microbiol Infect; 2002 Dec; 8(12):814-22. PubMed ID: 12519357
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Nagy E; Dowzicky MJ
Scand J Infect Dis; 2010; 42(1):33-8. PubMed ID: 19883155
[TBL] [Abstract][Full Text] [Related]
37. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
Shore KP; Pottumarthy S; Morris AJ
N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
[TBL] [Abstract][Full Text] [Related]
38. [Specificity of the anaerobic bacterial infections in the surgical and orthopedic wards].
Kierzkowska M; Majewska A; Sawicka-Grzelak A; Młynarczyk A; Ładomirska-Pestkowska K; Młynarczyk G
Med Dosw Mikrobiol; 2012; 64(1):29-34. PubMed ID: 22808727
[TBL] [Abstract][Full Text] [Related]
39. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
Arias CA; Singh KV; Panesso D; Murray BE
Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
